Symbols / THMO $0.00 +0.00% ThermoGenesis Holdings, Inc.

Healthcare • Medical Devices • United States • PNK
THMO Chart
About

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Medical Devices Market Cap 1.58K
Enterprise Value 4.33M Income -14.74M Sales 9.61M
Book/sh 0.12 Cash/sh 0.15 Dividend Yield —
Payout 0.00% Employees 25 IPO —
P/E — Forward P/E 0.00 PEG —
P/S 0.00 P/B 0.00 P/C —
EV/EBITDA -0.89 EV/Sales 0.45 Quick Ratio 0.28
Current Ratio 0.52 Debt/Eq — LT Debt/Eq —
EPS (ttm) -3.98 EPS next Y 0.20 EPS Growth —
Revenue Growth 6.40% Earnings 2024-05-17 17:00 ROA -25.50%
ROE -8.02% ROIC — Gross Margin 21.10%
Oper. Margin -20.35% Profit Margin -153.43% Shs Outstand 15.85M
Shs Float 1.76M Short Float 0.30% Short Ratio 1.44
Short Interest — 52W High 0.00 52W Low 0.00
Beta 16.98 Avg Volume 343.00 Volume 100.00
Target Price — Recom None Prev Close $0.00
Price $0.00 Change 0.00%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-0.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-11-14 reit HC Wainwright & Co. Buy → Buy $5
2023-08-11 reit HC Wainwright & Co. Buy → Buy $5
2023-05-16 reit HC Wainwright & Co. Buy → Buy $5
2023-04-03 reit HC Wainwright & Co. — → Buy $5
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-06-28 XU XIAOCHUN Chief Executive Officer — 7,894,737 $0.38 $3,000,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Revenue
9.45
-9.90%
10.48
+12.79%
9.29
Operating Revenue
9.45
-9.90%
10.48
+12.79%
9.29
Cost Of Revenue
7.51
-3.33%
7.77
+33.99%
5.80
Reconciled Cost Of Revenue
7.51
-3.33%
7.77
+33.99%
5.80
Gross Profit
1.93
-28.75%
2.71
-22.42%
3.49
Operating Expense
8.51
-4.47%
8.90
-16.98%
10.72
Research And Development
1.28
-22.60%
1.66
-24.90%
2.21
Selling General And Administration
7.22
-0.32%
7.24
-14.93%
8.52
Total Expenses
16.02
-3.94%
16.68
+0.91%
16.52
Operating Income
-6.57
-6.15%
-6.19
+14.35%
-7.23
Total Operating Income As Reported
-8.61
-39.03%
-6.19
+14.35%
-7.23
EBITDA
-7.74
-46.87%
-5.27
-2.45%
-5.14
Normalized EBITDA
-5.38
-2.05%
-5.27
+9.08%
-5.80
Reconciled Depreciation
1.15
+23.87%
0.93
+46.29%
0.63
EBIT
-8.89
-43.43%
-6.20
-7.25%
-5.78
Total Unusual Items
-2.36
0.00
-100.00%
0.65
Total Unusual Items Excluding Goodwill
-2.36
0.00
-100.00%
0.65
Special Income Charges
-2.36
0.00
-100.00%
0.65
Other Special Charges
0.33
—
-0.65
Write Off
2.04
0.00
—
Net Income
-17.98
-59.49%
-11.27
+0.96%
-11.38
Pretax Income
-18.92
-60.17%
-11.81
+0.57%
-11.88
Net Non Operating Interest Income Expense
-10.03
-78.63%
-5.62
+7.98%
-6.10
Interest Expense Non Operating
10.03
+78.63%
5.62
-7.98%
6.10
Net Interest Income
-10.03
-78.63%
-5.62
+7.98%
-6.10
Interest Expense
10.03
+78.63%
5.62
-7.98%
6.10
Other Income Expense
-2.31
-77000.00%
-0.00
-100.21%
1.45
Other Non Operating Income Expenses
0.05
+1733.33%
-0.00
-100.37%
0.80
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-18.92
-60.17%
-11.81
+0.57%
-11.88
Net Income From Continuing Operation Net Minority Interest
-17.98
-59.49%
-11.27
+0.96%
-11.38
Net Income From Continuing And Discontinued Operation
-17.98
-59.49%
-11.27
+0.96%
-11.38
Net Income Continuous Operations
-18.92
-60.17%
-11.81
+0.57%
-11.88
Minority Interests
0.94
+74.17%
0.54
+8.18%
0.50
Normalized Income
-15.61
-38.54%
-11.27
+6.33%
-12.03
Net Income Common Stockholders
-17.98
-59.49%
-11.27
+0.96%
-11.38
Diluted EPS
-7.59
+30.15%
-10.87
+74.97%
-43.41
Basic EPS
-7.59
+30.15%
-10.87
+74.97%
-43.41
Basic Average Shares
2.37
+128.33%
1.04
+295.65%
0.26
Diluted Average Shares
2.37
+128.33%
1.04
+295.65%
0.26
Diluted NI Availto Com Stockholders
-17.98
-59.49%
-11.27
+0.96%
-11.38
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Assets
11.23
-42.06%
19.39
-6.13%
20.65
Current Assets
5.18
-52.41%
10.88
-27.27%
14.96
Cash Cash Equivalents And Short Term Investments
2.00
-52.12%
4.18
-42.62%
7.28
Cash And Cash Equivalents
2.00
-52.12%
4.18
-42.62%
7.28
Receivables
0.95
-49.12%
1.86
+154.43%
0.73
Accounts Receivable
0.95
-49.12%
1.86
+154.43%
0.73
Gross Accounts Receivable
0.95
-52.68%
2.01
+126.55%
0.89
Allowance For Doubtful Accounts Receivable
-0.00
+97.32%
-0.15
+4.49%
-0.16
Inventory
1.41
-57.83%
3.33
-37.95%
5.37
Prepaid Assets
—
—
1.58
Other Current Assets
0.82
-45.29%
1.51
-4.44%
1.58
Total Non Current Assets
6.05
-28.82%
8.50
+49.47%
5.69
Net PPE
5.80
+11.98%
5.18
+182.53%
1.83
Gross PPE
13.37
+8.26%
12.35
+42.62%
8.66
Accumulated Depreciation
-7.58
-5.57%
-7.17
-5.08%
-6.83
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
8.61
+14.79%
7.50
+4.75%
7.16
Other Properties
3.21
-18.15%
3.92
+586.87%
0.57
Leases
1.55
+66.85%
0.93
+0.00%
0.93
Goodwill And Other Intangible Assets
0.00
-100.00%
2.07
-1.52%
2.10
Goodwill
0.00
-100.00%
0.78
+0.00%
0.78
Other Intangible Assets
—
1.29
-2.43%
1.32
Other Non Current Assets
0.26
-79.67%
1.26
-28.34%
1.76
Total Liabilities Net Minority Interest
14.82
-7.76%
16.06
-6.91%
17.25
Current Liabilities
11.76
+2.20%
11.51
+81.30%
6.35
Payables And Accrued Expenses
1.96
-27.78%
2.71
-29.75%
3.86
Payables
0.95
+15.61%
0.82
-35.94%
1.28
Accounts Payable
0.95
+15.61%
0.82
-35.94%
1.28
Current Accrued Expenses
1.01
-46.59%
1.89
-26.68%
2.58
Current Debt And Capital Lease Obligation
7.66
+13.61%
6.74
+728.91%
0.81
Current Debt
7.66
+13.61%
6.74
+728.91%
0.81
Other Current Borrowings
7.66
+13.61%
6.74
+728.91%
0.81
Current Deferred Liabilities
0.67
-14.32%
0.78
+8.76%
0.72
Current Deferred Revenue
0.67
-14.32%
0.78
+8.76%
0.72
Other Current Liabilities
1.48
+15.74%
1.28
+33.44%
0.96
Total Non Current Liabilities Net Minority Interest
3.05
-32.94%
4.55
-58.25%
10.91
Long Term Debt And Capital Lease Obligation
2.90
-20.02%
3.63
-62.40%
9.64
Long Term Debt
—
—
9.24
Long Term Capital Lease Obligation
2.90
-20.02%
3.63
+811.06%
0.40
Non Current Deferred Liabilities
0.13
-86.06%
0.91
-26.77%
1.24
Non Current Deferred Revenue
0.13
-86.06%
0.91
-26.77%
1.24
Other Non Current Liabilities
0.03
+58.82%
0.02
-15.00%
0.02
Stockholders Equity
-1.67
-138.80%
4.30
+12.23%
3.83
Common Stock Equity
-1.67
-138.80%
4.30
+12.23%
3.83
Capital Stock
0.00
+300.00%
0.00
0.00
Common Stock
0.00
+300.00%
0.00
0.00
Preferred Stock
0.00
0.00
0.00
Share Issued
3.62
+248.83%
1.04
+291.81%
0.26
Ordinary Shares Number
3.62
+248.83%
1.04
+291.81%
0.26
Additional Paid In Capital
282.38
+4.44%
270.38
+0.71%
268.46
Retained Earnings
-284.17
-6.75%
-266.19
-0.58%
-264.66
Gains Losses Not Affecting Retained Earnings
0.11
+2.70%
0.11
+258.06%
0.03
Minority Interest
-1.92
-97.02%
-0.97
-125.75%
-0.43
Other Equity Adjustments
0.11
+2.70%
0.11
+258.06%
0.03
Total Equity Gross Minority Interest
-3.58
-207.85%
3.32
-2.18%
3.40
Total Capitalization
-1.67
-138.80%
4.30
-67.14%
13.07
Working Capital
-6.58
-953.12%
-0.62
-107.25%
8.62
Invested Capital
5.99
-45.73%
11.04
-20.53%
13.89
Total Debt
10.56
+1.84%
10.37
-0.87%
10.46
Net Debt
5.66
+120.77%
2.56
-7.78%
2.78
Capital Lease Obligations
2.90
-20.02%
3.63
+811.06%
0.40
Net Tangible Assets
-1.67
-174.79%
2.23
+28.92%
1.73
Tangible Book Value
-1.67
-174.79%
2.23
+28.92%
1.73
Interest Payable
0.63
-57.51%
1.49
-33.12%
2.23
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-3.72
+48.91%
-7.28
-10.02%
-6.62
Cash Flow From Continuing Operating Activities
-3.72
+48.91%
-7.28
-10.02%
-6.62
Net Income From Continuing Operations
-18.92
-60.17%
-11.81
+0.57%
-11.88
Depreciation Amortization Depletion
1.15
+23.87%
0.93
+46.29%
0.63
Depreciation And Amortization
1.15
+23.87%
0.93
+46.29%
0.63
Other Non Cash Items
8.30
+138.17%
3.49
-3.97%
3.63
Stock Based Compensation
0.04
-85.39%
0.27
-89.57%
2.56
Provisionand Write Offof Assets
1.36
+103.45%
0.67
-22.80%
0.86
Asset Impairment Charge
2.04
+101700.00%
0.00
+103.57%
-0.06
Operating Gains Losses
0.33
+2863.64%
0.01
+101.69%
-0.65
Gain Loss On Sale Of PPE
0.00
-100.00%
0.01
0.00
Change In Working Capital
1.99
+339.23%
-0.83
+51.69%
-1.72
Change In Receivables
0.92
+180.69%
-1.13
-261.31%
0.70
Changes In Account Receivables
0.92
+180.69%
-1.13
-261.31%
0.70
Change In Inventory
1.57
-24.07%
2.07
+301.07%
-1.03
Change In Prepaid Assets
0.68
+590.65%
-0.14
+80.14%
-0.70
Change In Payables And Accrued Expense
0.23
+121.16%
-1.07
-1550.00%
0.07
Change In Accrued Expense
0.10
+114.12%
-0.69
-564.19%
0.15
Change In Payable
0.13
+133.68%
-0.39
-421.62%
-0.07
Change In Account Payable
0.13
+133.68%
-0.39
-421.62%
-0.07
Change In Other Working Capital
-1.59
-79.17%
-0.89
-100.45%
-0.44
Change In Other Current Liabilities
0.18
-45.15%
0.33
+202.17%
-0.32
Investing Cash Flow
-1.73
-333.25%
-0.40
-330.11%
-0.09
Cash Flow From Continuing Investing Activities
-1.73
-333.25%
-0.40
-330.11%
-0.09
Capital Expenditure
-1.73
-333.25%
-0.40
-330.11%
-0.09
Capital Expenditure Reported
-1.73
-333.25%
-0.40
-330.11%
-0.09
Financing Cash Flow
3.28
-28.52%
4.59
-32.87%
6.83
Cash Flow From Continuing Financing Activities
3.28
-28.52%
4.59
-32.87%
6.83
Net Common Stock Issuance
2.86
-37.66%
4.58
-32.92%
6.83
Proceeds From Stock Option Exercised
0.42
+13933.33%
0.00
0.00
Changes In Cash
-2.18
+29.74%
-3.10
-2702.52%
0.12
Effect Of Exchange Rate Changes
-0.00
+83.33%
-0.01
0.00
Beginning Cash Position
4.18
-42.62%
7.28
+1.66%
7.16
End Cash Position
2.00
-52.12%
4.18
-42.62%
7.28
Free Cash Flow
-5.45
+29.01%
-7.68
-14.45%
-6.71
Interest Paid Supplemental Data
1.63
-41.88%
2.81
+18.03%
2.38
Change In Interest Payable
0.12
+116.26%
-0.74
-595.30%
0.15
Common Stock Issuance
2.86
-37.66%
4.58
-32.92%
6.83
Issuance Of Capital Stock
2.86
-37.66%
4.58
-32.92%
6.83
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category